Zhejiang Shapuaisi Pharmaceutical Co (SHSE:603168) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Zhejiang Shapuaisi Pharmaceutical Co EBITDA Margin % Related Terms
Zhejiang Shapuaisi Pharmaceutical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Shapuaisi Pharmaceutical Co EBITDA Margin % Chart
SHSE:603168 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Shapuaisi Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Shapuaisi Pharmaceutical Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Shapuaisi Pharmaceutical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Zhejiang Shapuaisi Pharmaceutical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Shapuaisi Pharmaceutical Co (SHSE:603168) has a EBITDA Margin % of -24.31% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zhejiang Shapuaisi Pharmaceutical Co and its competitors. According to the industry distribution chart, Zhejiang Shapuaisi Pharmaceutical Co ranks #852 out of 952 companies in the Drug Manufacturers industry, placing it in the top 89.5%.
Is Zhejiang Shapuaisi Pharmaceutical Co's EBITDA Margin % too high?
Zhejiang Shapuaisi Pharmaceutical Co's current EBITDA Margin % is -24.31%. Based on the distribution chart, Zhejiang Shapuaisi Pharmaceutical Co ranks #852 out of 952 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Zhejiang Shapuaisi Pharmaceutical Co has a GF Score™ of 37/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Shapuaisi Pharmaceutical Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Zhejiang Shapuaisi Pharmaceutical Co ranks #852 out of 952 companies for EBITDA Margin %. This places Zhejiang Shapuaisi Pharmaceutical Co in the lower half of its industry. The industry median EBITDA Margin % is 12.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zhejiang Shapuaisi Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Shapuaisi Pharmaceutical Co's current EBITDA Margin % is -24.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Shapuaisi Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Shapuaisi Pharmaceutical Co (SHSE:603168) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥8.52, compared to a current price of ¥4.74 — trading 44.4% below its estimated fair value. The current EBITDA Margin % is -24.31%. Zhejiang Shapuaisi Pharmaceutical Co's overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Zhejiang Shapuaisi Pharmaceutical Co (SHSE:603168), the current EBITDA Margin % is -24.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Shapuaisi Pharmaceutical Co (SHSE:603168) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Shapuaisi Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥4.74 is trading 44.4% below its estimated GF Value™ of ¥8.52.
GuruFocus considers Zhejiang Shapuaisi Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for SHSE:603168:
EBITDA Margin %: -24.31%
GF Value™: ¥8.52 vs. price of ¥4.74 (44.4% below fair value)
No single metric tells the full story. See the SHSE:603168 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Shapuaisi Pharmaceutical Co Business Description
Zhejiang Shapuaisi Pharmaceutical Co Ltd is a China based pharmaceutical company. It is engaged in drug research and development, production and operation. The product portfolio of the company includes oral solutions, eye drops, tablets, hard capsules, suppositories, granules, raw materials dosage forms such as medicines, rinsing agent and mixture, and others. The company operates pharmaceutical manufacturing companies, pharmaceutical sales company, pharmaceutical retail company and pharmaceutical research institute. The products offered by the company are sold in China and are also exported to the other countries.
37GF Score
Get the complete analysis for SHSE:603168
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603168 has been successfully added to your 
